BioSpace News Archive

Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 85,250 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

Financing accelerates Werewolf’s pipeline of systemically delivered, conditionally activated INDUKINE™ molecules into clinical stage development and supports efforts to build a leading immuno-oncology drug discovery and development team

Korro Bio, Inc. , a biotechnology company developing single-base RNA editing therapies, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present an update on Korro’s progress at the 39 th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Thursday, January 14, 2021 at 8:05 a.m. E.T. using a virtual platform. About Korro Bio, Inc. Korro is leading the